CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer

Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are two chronic conditions, very common in aged men, that have been associated to inflammatory process. Chemokines and their receptors are recognized as critical mediators of inflammatory responses, they regulate immune cell migration and are implicated in tumor pathogenesis. The impact of two chemokine receptor gene polymorphisms, CCR2-64I (rs1799864) and CCR5-Δ32 (rs333), was evaluated in BPH and PCa. 385 DNA samples (130 BPH, 136 PCa, 119 healthy control) were genotyped. The allele frequencies were similar among control, BPH and PCa groups. Median of serum PSA levels was different between groups: 0.79, 1.45 and 6.91 ng/mL in control, BPH and PCa groups, respectively (all p < 0.001). The prostate volume median was 20.00 cm³ in the control group, thus, lower than BPH (35.35 cm³) and PCa (35.80 cm³) (both p < 0.001), nevertheless no statistical significant difference was observed between BPH and PCa patients (p = 0.172). Remarkably, CCR2-64I was a protective factor to PCa when compared with BPH (OR = 0.550; 95%CI = 0.311–0.975), although the statistically significant difference was lost after correction for multiple comparisons. No significant associations of CCR5-Δ32 variant were observed with BPH, PCa or PCa clinicopathologic status. Our data suggest the influence of CCR2-64I variant in the development of prostate cancer.